|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the expression levels of cluster of differentiation (CD)146 and vascular endothelial growth factor A (VEGFA) in epithelial ovarian cancer, and their clinical significance.
|
30675307 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
CircRhoC promotes tumorigenicity and progression in ovarian cancer by functioning as a miR-302e sponge to positively regulate VEGFA.
|
31639291 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) promotes progression of ovarian cancer.
|
30348916 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We determined if nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors has antitumor activity in bevacizumab-resistant recurrent EOC, tubal, and peritoneal cancer.
|
30929823 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
|
31200683 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA‑655 inhibits cell proliferation and invasion in epithelial ovarian cancer by directly targeting vascular endothelial growth factor.
|
29845206 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to determine whether the combination of triapine (ribonucleotide reductase inhibitor), cediranib (vascular endothelial growth factor receptor tyrosine kinase inhibitor), and the PARP inhibitor olaparib synergized against BRCA wild-type and HRR-proficient EOC in xenograft mouse models.
|
30444904 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.
|
29416352 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oxytocin inhibits ovarian cancer metastasis by repressing the expression of MMP-2 and VEGF.
|
29721047 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AEG-1, HIF-1<i>α</i>, and VEGF amounts were significantly elevated in EOC tissue samples compared with normal ovary specimens (<i>p</i> < 0.001).
|
29770329 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages I-II.
|
30066848 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the expression and prognostic significance of TBC1D16 in EOC and its relationship with the expression of vascular endothelial growth factor (VEGF).
|
29962380 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer.
|
29308068 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This acellular fraction contains multiple growth factors including IL-6 and VEGF-A, which were exploited to establish their bio-marker significance in EOC patients.
|
29572186 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate mRNA expression of NCK2, integrins and VEGFA in OvCa cell lines, qRT-PCR was performed.
|
29218693 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present meta-analysis indicated that positive/high expression of tissue VEGF may have a close association with survival of ovarian cancer.
|
30093968 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, this study provides an insight into the mechanism governing elevated VEGF-autocrine functioning in OC that contributes to its invasive/metastatic behavior.
|
29904943 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tumour tissue of 100 patients with EOC was analysed for protein expression of vascular endothelial growth factor (VEGF)-A, -C, -D by Western Blot analysis.
|
28591727 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, human ovarian surface epithelial (HOSE) and epithelial ovarian cancer (A2780) cell lines were stimulated with estradiol, where NGF and VEGF protein levels were evaluated.
|
28116735 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Members of vascular endothelial growth factor (VEGF) family are overexpressed in EOC and play key roles in its malignant progression though their contribution in development of the chemoresistant disease remains elusive.
|
28383032 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of four genetic polymorphisms in the vascular endothelial growth factor-A gene and development of ovarian cancer: a meta-analysis.
|
29069849 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the relationship among SPARC, VEGFs and lymph node metastasis in ovarian cancer.
|
29075785 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.
|
27780361 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor serum levels were analyzed in patients with EOC.
|
28574932 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we demonstrated that the upregulation of SP1 enhanced expression of VEGF promoting the angiogenesis and migration of trastuzumab-resistant ovarian cancer cell line SKOV3-T. Our in vitro and in vivo results both gave evidence that the SP1-VEGF axis was responsible for the enhanced malignancy, angiogenesis and migration in the acquired trastuzumab-resistant ovarian cancer cell model.
|
29048687 |
2017 |